Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Analysis of the Off-Target Characteristics
of the CETP Inhibitors
� Clinical evidence of increased BP
� Preclinical evidence of increased aldosterone production*
�
Preclinical evidence of aldosterone synthase (CYP11B2)
mRNA induction*
� Preclinical evidence of RAAS-associated gene induction*
� L-type Ca 2+ channel activation*
1 Barter P, et al. N Engl J Med. 2007;357:2109–2122; 2 Masson D. Curr Opin Invest Drugs. 2009;10:980-987;
3 Stein E, et al. Am J Cardiol. 2009;104:82–91; 4 Forrest MJ, et al. Br J Pharmacol 2008;154:1465–1473;
5 Stroes ES, et al. Br J Pharmacol. 2009;158:1763–1770; 6 Clerc RG, et al. J Hypertens. 2010;28(8):1676-
1686.